Biota Pharmaceuticals’ slow trip downward continued Friday as the company disclosed that its its lead program, a flu treatment called laninamivir octanoate, failed to beat out placebo in a midstage study, sending its shares to an all-time nadir.

…read more

Source: Biota tanks as its flu drug comes up empty in Phase II


0 No comments